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My 40-year history with Cronobacter/
Enterobacter sakazakii – lessons 
learned, myths debunked, and 
recommendations
John J. Farmer III 1,2* 
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Mountain, GA, USA
Much has been learned about organism in the Cronobacter/Enterobacter sakazakii com-
plex since I first named and described Enterobacter sakazakii in 1980. However, there 
are still wide knowledge gaps. One of the most serious is that are still many uncertainties 
associated with assessing the public health risk posed by these bacteria, particularly in 
neonatal meningitis. Over the last few decades, Cronobacter contamination of commercial 
powdered infant formula products has apparently been reduced, but it is still an ongoing 
problem. The powdered infant formula industry still cannot produce powdered formula 
that is free of bacterial contamination with Cronobacter, other Enterobacteriaceae, other 
pathogenic bacteria, and other microorganisms. Until this happens, infants and other will 
be at risk of becoming infected when they ingest contaminated formula.
Keywords: Cronobacter, Enterobacter sakazakii, powdered infant formula, safety, neonatal meningitis, risk 
assessment, government regulations, recommendations
introduction
“Those who don’t know history are destined to repeat it.”  –  Edmund Burke (1729–1797, British 
Statesman and Philosopher). In this review, I look at this familiar quotation in the context of my 40+ 
year-history with Cronobacter – Enterobacter sakazakii plus its sibling organisms that are now classi-
fied in the genus Cronobacter. There are now over 600 papers about this genus of Enterobacteriaceae; 
however, there are many myths and some knowledge gaps. There are also misconceptions and 
statements being made that simply are not supported by fact. Many of these are based on the lack 
of knowledge about the organism’s early history and the first few decades of research that laid the 
foundation for our current knowledge. The purpose of this review is to debunk, correct, clarify, and 
recommend. It is based on my long history and many different experiences with “Esak.”
Cronobacter researcher Stephen J. Forsythe wrote a paper in 2012 with an intriguing title – “Myths 
and legends of Cronobacter – a new bacterial pathogen of babies?” (1). In this short paper, he listed 
and described seven items that he called “myths.” I really like his idea and wish to expand the discus-
sion he started. Each of my discussion items will be in the form of one of the followings: observation, 
fact, question, myth, or recommendation.
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History
Facts: The first documented Cronobacter isolate dates back only 
to 1950. The first strain isolated from a human clinical specimen 
was in 1953. The first documented case of neonatal meningitis 
was in 1958 (see below).
The recorded history for Cronobacter organisms is short but 
they have certainly existed for millions of years (tens of millions 
of years? hundreds of millions of years?). It is only within the last 
few years that we have understood the complexity of the group 
and begun to use precise and accurate names in describing the 
species, subspecies, biogroups, and other subgroups, such as 
ribotypes, PFGE pattern types, and sequence types.
1890’s to the 1920’s: The bacteriological era was in its infancy. 
Bacteria were being described and named but with incomplete 
and imprecise descriptions. Many yellow-pigmented bacteria 
were described, given names, and classified in many different 
genera. A partial list includes: “coliform,” “yellow-pigmented 
coliform bacteria,” “pigmented cloacae A,” “Serratia species,” 
“Enterobacter species,” “Erwinia species,” “Chromobacterium 
typhiflavum,” “Chromobacterium species,” “unidentified 
Enterobacteriaceae,” and perhaps other names. The term “yellow 
pigmented coliform” was a vernacular term that appeared in 
the literature. It would include strains of Enterobacteriaceae that 
produce a yellow pigment and fermented lactose and produced 
gas during this fermentation. An organism described as a “yellow 
pigmented coliform” could be E. sakazakii or could be one of the 
other species or biogroups of Enterobacteriaceae that share these 
few phenotypic properties. When a culture with one of the above 
names exits in a culture collection, it can be tested with current 
methods to determine its correct identification and name. This was 
done with the cultures deposited in England’s National Collection 
of Type Cultures (NCTC) and several were determined to be in 
the Enterobacter sakazakii complex as described in Farmer et al. 
(2). Unless cultures were preserved, it is impossible to determine 
their correct identification based on today’s knowledge.
1929: A case of septicemia due to a “pigmented coliform” was 
described by Pangalos (3) who proposed the name Bacillus rubro-
luteus. However, some of the characteristics of this bacterium 
do not fit those of E. sakazakii: growth in broth was uniformly 
turbid (“Le bacille pousse sur bouillon en donnant un trouble 
homogené.”) in contrast to the growth of E. sakazakii, which char-
acteristically settles to the bottom, leaving the upper layer clear; 
the pigment was yellow-brick rather than yellow “like Bacterium 
flavum.” The isolate was from a woman suffering from a febrile 
infection after curettage; not from a newborn. The organism 
was later renamed Serratia rubroluteum. No cultures of Serratia 
rubroluteum have apparently survived, so it is not possible to 
determine its true identity based on current knowledge.
1950: A strain of Enterobacteriaceae was isolated from a “tin 
of dried milk” and was sent to England’s National Collection of 
Type Cultures (NCTC). There it was given the designation NCTC 
8155. It was re-characterized in the late 1970’s and identified as E. 
sakazakii biogroup 1 (2). This is the earliest date for a strain of this 
organism and is also the first documented isolate of Cronobacter 
from food and from a “dried milk” type of product. In 2011, 
Joseph and Forsyth (4) reported additional results for this strain, 
which they had obtained and then studied about 60 years after 
it was first isolated. They determined that is was “Cronobacter 
sakazakii sequence type 4,” which they found to be “a highly stable 
clone with a high propensity for neonatal meningitis.”
1953: A strain from abdominal pus was submitted to NCTC 
and given the designation NCTC 9238. It was later identified as 
E. sakazakii biogroup 1 (2). This is the earliest date of an isolate 
of Cronobacter from a human clinical specimen.
1954: A strain from water was submitted to NCTC and 
given the designation NCTC 9529. This isolate came from the 
Metropolitan Water Board. It is most likely was not isolated from 
drinking (potable) water, but may have come from the river water 
entering the treatment works rather than post-treatment (Barry 
Holmes, Director of NCTC, personal communication). It was 
identified as E. sakazakii, and then re-studied later. According 
to Joseph et al. (5) and to http://bacteria.ensembl.org/cronobac-
ter_universalis_nctc_9529/Info/Annotation/# about this organ-
ism’s correct identification is Cronobacter universalis. This is the 
first documented water/environmental isolate of Cronobacter.
1958: This is the first documented neonatal meningitis case 
and the first documented outbreak (2 cases) due to E. sakazakii. 
It occurred at Osterhills Hospital (St. Albans City Hospital), 
England (6). The organism was identified as a “pigmented 
coliform bacterium.” Fortunately, these isolates were sent to M. 
T. Parker, of the Manchester (England) Public Health Laboratory 
who studied and preserved them.
1961: Urmenyi and White-Franklin publish their report about 
the Osterhills Hospital meningitis cases in The Lancet and used 
the term “pigmented coliform” in the title of the manuscript (6).
1965: The second documented case of meningitis due to E. 
sakazakii occurred at the city and county hospital of Odense, 
Denmark (7). This isolate was compared by M. T. Parker to the 
1958 Osterhills Hospital isolates, and it was almost identical to 
the strains isolated in 1958. These organisms were again identi-
fied as a yellow-pigmented Enterobacter cloacae rather than as 
Enterobacter sakazakii.
1972 to 1976: DNA–DNA hybridization experiments showed 
that Enterobacter cloacae and yellow-pigmented E. cloacae were 
closely related, but the genetic relationship was not close enough 
to be classified as belonging to the same species (8, 9).
1977: The name Enterobacter sakazakii first appeared in print. 
This was in a widely distributed CDC publication (10). I also used 
this name in an oral presentation at the 1977 American Society 
for Microbiology national meeting.
1977–79: The name Enterobacter sakazakii was not validly 
published under the rules of the Bacteriological Code and should 
have appeared in parentheses and written as “Enterobacter 
sakazakii.”
1980: The name Enterobacter sakazakii was “officially pub-
lished” according to the rules of the Bacteriological Code, and 
thus the name became a validly published species that can be 
written as – Enterobacter sakazakii, Farmer et al. (2). The species 
description included 15 subgroups, which were classified and 
named as 15 distinct biogroups. Biogroup 15 was very different 
in its biochemical properties from the other 14 biogroups. We 
speculated that this unusual biogroup might eventually be classi-
fied as a separate species, which indeed it was, 27 years later (11).
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1980 onward: Once Enterobacter sakazakii was named and 
described, case reports of E. sakazakii neonatal meningitis and 
other papers about it began to appear in the literature.
1980 to 2007: From 1980 to 2007, Enterobacter sakazakii was 
considered to be a single well-defined bacterial species with 15 
biogroups as named and described in the original paper (2). 
During this time, commercial and other identification systems 
and methods gave an identification of Enterobacter sakazakii (or 
Enterobacter cloacae). Each of these identifications needs to be 
reevaluated based on the establishment of Cronobacter in 2007 
(see below).
1983: Muytjens et  al. (12) summarize eight neonatal men-
ingitis and sepsis cases of Enterobacter sakazakii from The 
Netherlands. This was the first large series of neonatal infections 
to be reported and the first outbreak with a thorough analysis. 
The cases were over a 4-year time period (1977–81) and com-
prised all the Enterobacter sakazakii cases detected in the entire 
country.
1987: Muytjens et al. (13) studied the contamination rate of 
commercial powdered formula products produced in 35 different 
countries. They found E. sakazakii and other Enterobacteriaceae 
were common contaminants. E. sakazakii was detected in pow-
dered formula made in 13 different countries. This paper really 
marked the beginning of the association of E. sakazakii with pow-
dered formula. This association and the danger of contaminated 
powdered formula was emphasized in an editorial by Muytjens 
and Kollée (14).
1988: This is the date of the first documented E. sakazakii 
outbreak in the United States (15). There were two bacteremia 
cases and two additional cases of colonization in a neonatal 
intensive care unit. All four infants had been fed a powdered 
protein hydrolyzate formula that had been mixed in a blender. 
The blender and an open can of the powdered protein hydrolyz-
ate formula were cultured and found to be contaminated with 
Enterobacter sakazakii. This raised the question that does not 
have an answer – did the powdered formula contain Enterobacter 
sakazakii and contaminate the blender, or did the contaminated 
blender contaminate the formula?
2001: There was an outbreak of Enterobacter sakazakii at 
a Tennessee hospital with one case of meningitis and eight 
additional cases with Enterobacter sakazakii colonization. It was 
caused when infants were fed Portagen, a commercial powdered 
formula produced by Mead Johnson. This outbreak marked the 
beginning of the U. S. Food and Drug Administration’s interest 
in contamination of powdered infant formula products and 
especially contamination with Enterobacter sakazakii.
2002, April 11: In response to the Portagen outbreak, the U. S. 
Food and Drug Administration issued a letter to American health 
community: “Health Professionals Letter on Enterobacter saka-
zakii Infections Associated with Use of Powdered (Dry) Infant 
Formulas in Neonatal Intensive Care Units.” (16)
2002, July 26: In response to the Portagen outbreak, the U. S. 
Food and Drug Administration began a program to determine the 
degree of E. sakazakii contamination of powdered infant formula 
products (and associated raw ingredients) made by American 
companies (17). This FDA study determined that 5 of 22 (22.7%) 
of the batched samples of “finished product” were contaminated 
with E. sakazakii (18). Two of 69 samples of raw ingredients were 
contaminated with E. sakazakii (18).
2003, March 18–19: In further responses to the Portagen out-
break, the Food Advisory Committee of the U. S. Food and Drug 
Administration held a meeting of experts to discuss E. sakazakii 
infections in babies and infants with emphasis on contamina-
tion of powdered infant formula made by U. S. companies. At 
the meeting Dr. Don Zink presented the results from the FDA 
sampling and testing for E. sakazakii described above.
Ref (19) gives the complete set of slides for all eight presenta-
tions that were given.
2004: The World Health Organization published the first of 
three books on Cronobacter/Enterobacter sakazakii (20).
2006: The World Health Organization published the second of 
three books on Cronobacter/Enterobacter sakazakii (21).
2007: Cronobacter was proposed as a new genus to include 
the organisms formerly classified as Enterobacter sakazakii. 
Cronobacter Iverson et al. – had eight different organisms includ-
ing four named species, one unnamed species, and five named 
subspecies:
Cronobacter sakazakii
Cronobacter sakazakii subspecies sakazakii
Cronobacter sakazakii subspecies malonaticus
Cronobacter dublinensis
Cronobacter dublinensis subspecies dublinensis
Cronobacter dublinensis subspecies lactaridi
Cronobacter dublinensis subspecies lausanensis
Cronobacter muytjensii
Cronobacter turicensis
Cronobacter genomospecies 1 (a distinct species, but unnamed)
2008: The World Health Organization published the third 
of three books on Cronobacter/Enterobacter sakazakii (22). 
The book Enterobacter sakazakii (23, 24) was published by the 
American Society for Microbiology in its series Emerging Issues 
in Food Safety.
2009, January 22–23: The First International Conference on 
Cronobacter (Enterobacter sakazakii) was held at O’Reilly Hall, 
University College, Dublin, Ireland1.
At this conference Dr. Angelica Lehner reported that 
Enterobacter sakazakii can be in a viable but non-culturable state 
and thus escape detection when only “normal” microbiological 
culturing methods are used.
2012–13: Three new species of Cronobacter were 
described  –  Cronobacter universalis, Cronobacter pulveris, and 
Cronobacter zurichensis.
2015: Ten species and three subspecies of Cronobacter have 
now been named, described, and have standing in nomenclature:
Cronobacter Iversen et al. (25)
Cronobacter condimenti Joseph et al. (5)
Cronobacter dublinensis Iversen et al. (25)
Cronobacter dublinensis subsp. dublinensis Iversen et al. (25)
Cronobacter dublinensis subsp. lactaridi Iversen et al. (25)
1 www.ucd.ie/crono09/
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Cronobacter dublinensis subsp. lausannensis Iversen et al. (25)
Cronobacter helveticus Brady et al. (26)
Cronobacter malonaticus Iversen et al. (25)
Cronobacter muytjensii Iversen et al.
Cronobacter pulveris Brady et al. (26)
Cronobacter sakazakii (2, 25)
Cronobacter turicensis Iversen et al. (25)
Cronobacter universalis Joseph et al. (5)
Cronobacter zurichensis Brady et al. (26)
See http://www.bacterio.net/cronobacter.html and http://
www.bacterio.net/-allnamesac.html for complete details for the 
above organisms and as a convenient way to find updates on 
new organisms in this genus and new organisms in other genera. 
Additional Cronobacter species probably exist but await discovery 
and description.
Nomenclature and Classification
Two myths: Enterobacter sakazakii had been moved to a new 
genus Cronobacter. All strains originally known as Enterobacter 
sakazakii are now Cronobacter sakazakii.
Most scientists are not familiar with the Bacteriological 
Code whose principals and rules govern the naming and clas-
sifying bacteria. Accurate statements in relation to the myths 
above are:
 (1) The original name and classification of this group of 
organisms now known as Cronobacter is “Enterobacter 
cloacae – yellow pigmented strains.” An even older name is 
“pigmented coliform.” However, most strains given the name 
“pigmented coliform” would probably not be Cronobacter if 
they could be re-studied and precisely identified.
 (2) The “first proposed reclassification” was by Farmer et  al. 
who named and described Enterobacter sakazakii. The name 
Enterobacter sakazakii was, and is, validly published and is 
available for those who might not agree with the proposed 
reclassification as the genus Cronobacter. A better and more 
precise term is “the Enterobacter sakazakii complex” which 
is equivalent to “Cronobacter species.”
 (3) The “second proposed reclassification” was that of Iversen 
et  al. who named and described Cronobacter with a total 
of 7 species/subspecies including Cronobacter sakazakii, the 
most important species.
 (4) All strains originally classified as Enterobacter sakazakii 
need to be re-studied to see which Cronobacter species they 
belong to. Many will be Cronobacter sakazakii, but some will 
be other Cronobacter species.
For example, almost 40 years ago I isolated an organism from 
my dog’s water bowl and identified it as Enterobacter sakazakii. 
Today, this strain could be revived from a CDC freezer and 
retested with one or more sensitive identification methods 
now available. Its correct identification may be Cronobacter 
sakazakii or it may be one of the other Cronobacter species. 
When this is done a statement such as the following can be 
written:
“The organism that Farmer isolated in 1978 from his 
dog’s water bowl (CDC strain 1167-78) was originally 
identified as E. sakazakii. In 2015 it was removed from 
a CDC freezer and re-tested. The new identification 
was Cronobacter dublinensis subspecies lactaridi* based 
on the following criteria: PCR analysis, 16S r-RNA 
sequence analysis ….”
*Or whatever this revised identification turns out 
to be
The “Farmer” in “Cronobacter sakazakii (Farmer et al. 1980) 
Iversen et al. 2008” means that Farmer is “claiming credit” for this 
scientific finding. I saw a version of this statement in a rebuttal of a 
report that I had written. It was written by a well-known Cronobacter 
expert in a report he prepared for a legal case. He claimed that I was 
claiming credit for this organism, and seemed to imply that I did not 
have any right to do this. The term “Cronobacter sakazakii (Farmer 
et al. 1980) Iversen et al. 2008” is merely the correct way to cite this 
name under the rules of the Bacteriological Code. It has nothing to do 
with “claiming credit” as this expert incorrectly stated. His statement 
was based on a misunderstanding of the correct way to cite a species 
name when a new genus name is proposed. See the Bacteriological 
Code, and http://www.bacterio.net/cronobacter.html to verify the 
correctness of the above myth debunking.
Question: Are there other organisms in the family 
Enterobacteriaceae that can be confused with Cronobacter when 
they are being identified? Yes, strains in the “Enterobacter cloacae 
complex” can easily be confused. Strains typically identified as 
Enterobacter cloacae fall into at least five DNA-DNA hybridiza-
tion groups depending on the operational definition used. The 
term “Enterobacter cloacae complex” might also include, or be 
confuses with, the organisms listed below (27):
Enterobacter cloacae DNA hybridization group 1
Enterobacter cloacae DNA hybridization group 2
Enterobacter cloacae DNA hybridization group 3
Enterobacter cloacae DNA hybridization group 4
Enterobacter cloacae DNA hybridization group 5
Enterobacter amnigenus
Enterobacter asburiae
Enterobacter cancerogenus
Enterobacter dissolvens
Enterobacter hormaechei
Enterobacter kobei
Enterobacter ludwigii
Enterobacter nimipressuralis
Enterobacter pyrinus
Enterobacter taylorae
Enteric Group 17
Others (depending on the operational definition used) such as 
some strains of Erwinia, Brenneria, Pantoea, Pectobacterium, 
Enterobacter ludwigii. For a more detailed analysis of this iden-
tification issue, see the discussions of Farmer et al. (27) in the 
Manual of Clinical Microbiology.
Question: Does the above discussions have anything to do with 
practical matters relating to Cronobacter? Yes. Every identification 
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of a Cronobacter strain should be taken “with a grain of salt” or 
even better, the entire box of salt. The reader should critically 
examine the method(s) use in determining the identification. This 
is a particular problem if commercial biochemical identification 
methods (“commercial ID kits”) are used. They are not sensitive 
in distinguishing all of the organisms described in the preceding 
paragraphs.
Questions: I have seen the terms “Enterobacter sakazakii (sensu 
lato)” and “Enterobacter sakazakii (sensu stricto)” – What exactly 
do they mean and why are these terms necessary? These terms 
are used to clarify the meaning of the words/terms “Enterobacter 
sakazakii” and “Cronobacter sakazakii.” They became necessary 
when the new genus Cronobacter was proposed in 2007. Below is 
a listing that should clarify this.
The organisms/terms below have the same definition and 
meaning and it is different from the names/organisms in the next 
grouping:
•	 Enterobacter sakazakii (sensu lato)
•	 Enterobacter sakazakii (in a broad sense, those strains highly 
related to the type strain plus those less related but still now 
considered to be species of Cronobacter)
•	 Enterobacter sakazakii group
•	 Enterobacter sakazakii as defined by Farmer et al. (2)
•	 Cronobacter species
The organisms/terms below have the same definition and 
meaning and it is different from those in the previous grouping:
•	 Enterobacter sakazakii (sensu stricto)
•	 Enterobacter sakazakii (in a strict sense, only those strains 
highly related to the type strain of Enterobacter sakazakii)
•	 Cronobacter sakazakii (only those strains highly related to the 
type strain of Cronobacter sakazakii and excluding all of the 
other Cronobacter species)
Question: What are some correct and incorrect usages of 
“Enterobacter sakazakii” from the pre-2007 literature?
Correct:
•	 In 1978, Farmer isolated a strain of Enterobacter sakazakii 
from his dog’s water bowl.
•	 In 1978, Farmer isolated a strain of Enterobacter sakazakii 
(sensu lato) from his dog’s water bowl.
•	 In 1978, Farmer isolated a strain of the Enterobacter 
sakazakii group from his dog’s water bowl.
•	 In 1978 Farmer isolated a strain of the Enterobacter 
sakazakii complex from his dog’s water bowl.
•	 In 1978, Farmer isolated a strain of Cronobacter from his 
dog’s water bowl.
•	 In 1978, Farmer isolated a Cronobacter species from his 
dog’s water bowl.
Incorrect:
•	 In 1978, Farmer isolated a strain of Cronobacter sakazakii 
from his dog’s water bowl.
This last sentence would become correct if the strain isolated 
from his dog’s water bowl were re-studied and found to be 
Cronobacter sakazakii, rather than one of the other species of 
Cronobacter. Until this is done, it is best to refer to this organism 
as “Cronobacter species.”
The Organisms and Their Properties
Fact: Cronobacter is a typical member of the family 
Enterobacteriaceae in many ways. This is documented in original 
1980 paper by Farmer et al. and further described in dozens of 
subsequent publications.
Fact: One simple way to recognize a strain of Cronobacter 
is to take advantage of the very unusual way that colonies of 
Cronobacter grow on microbiological plating media. I described 
these colonies on page 576 (2) as follows: “… either dry or 
mucoid, crenated (notched or scalloped), and rubbery when 
touched with a loop (very little growth was removed and the 
colony snapped back when touched).” I noted that the colonies 
were very different from the typical colonies produced by other 
members of the family Enterobacteriaceae which are smooth, 
moist, and non-rubbery.
Fact: Another simple way to recognize a strain of Cronobacter 
is that most strains produce a bright yellow pigment. The original 
study found that 97% of the stains studied did this and that pig-
ment production was much stronger at room 25°C than 36°C 
(2). However, the ability to produce yellow pigment was some-
times lost upon storage and subculture, which is true of other 
Enterobacteriaceae that produce distinct pigments.
Fact: Strains of Cronobacter can grow as individual cells, pairs 
of cells, and large clumps which contain hundreds/thousands of 
connected cells. This was shown in the original study (2).
Fact: Strains of Cronobacter can also grow as large sheets of 
cells called biofilms. This has been documented in many pub-
lished studies.
Fact: Strains of Cronobacter have phenotypic properties and 
genetic properties that can be used as “strain typing methods” in 
microbial forensic analysis. The use of these genetic properties in epi-
demiological studies and causation analysis is illustrated in Table 1.
Facts: Species/strains of Cronobacter have different patho-
genic potentials for causing meningitis in infants and babies. 
Cronobacter sakazakii sequence type 4 (C. sakazakii ST 4) is 
extremely important as a cause of neonatal meningitis. Joseph 
and Forsythe (4) studied a collection of 41 Cronobacter strains and 
found that they could be defined in terms of different “sequence 
types.” They gave “sequence types designations” for these that 
went from 1 to 41 (ST1 – ST41) (see Table 1 in their paper). A 
summary of findings from the paper:
•	 Of the 20 C. sakazakii ST4 strains, ten were from neonates; 
seven were from infants; one was from a child and the source 
of the other was unknown.
•	 Seven of the C. sakazakii ST4 strains had been isolated from 
spinal fluid, two were from cases of necrotizing enterocolitis 
and one was from a case of bacteremia.
•	 Half (20 of 41) of the C. sakazakii strains were ST4, and 9 of 
12 meningitis isolates were ST4.
•	 C. sakazakii ST4 appears to be a highly stable clone with a 
high propensity for neonatal meningitis.
TABLe 1 | example of how microbial forensic analysis can be used to “trace back” Cronobacter strains to a powdered formula factory – use of simple 
and reference (more complex) techniques to compare strains.
Characteristic Cronobacter strain 1 Cronobacter strain 2 Cronobacter strain 3 Cronobacter strain 4
3 simple techniques
Biotype [of Ref. (2)] Biotype 6, Indole+a Biotype 6, Indole+a Biotype 6, Indole+a Biotype 1, Indole−a
Bionumber in the Vitek 
commercial test system
662475167Bb 662475167Bb 662475167Bb 662475467Bb
Antibiotic susceptibility pattern Pattern 1 – sensitive to all Pattern 1 – sensitive to all Pattern 1 – sensitive to all Pattern 6 – tetracycline resistant
5 reference techniques
Plasmid profile Pattern 1 Pattern 1 Pattern 1 Pattern 7a
PFGE – enzyme 1 Pattern 1 Pattern 1 Pattern 1 Pattern 14
PFGE – enzyme 2 Pattern 1 Pattern 1 Pattern 1 Pattern 19
MLVA Pattern a Pattern a Pattern a Pattern c
Multilocus sequence typing 
(MLST) of Joseph et al.
Type 4 Type 4 Type 4 Type 1
Ribotype Type 2 Type 2 Type 2 Type 9
Final identification Cronobacter sakazakii 
sequence type 4
Cronobacter sakazakii 
sequence type 4
Cronobacter sakazakii 
sequence type 4
Cronobacter sakazakii sequence 
type 1
aBiotype 6, Indole+ is a very unusual biotype, but Biotype 1, Indole− is a very common biotype [see Table 3 of Ref. (2)].
bIndole production is also one of the tests in this commercial identification system. Thus, Cronobacter strains that are indole positive have a different bionumber than strains that are 
indole negative (contrasting numbers are highlighted in bold type above).
Conclusion: Although the two cases of neonatal meningitis are separated in both time and geography, they were both probably, to a high degree of scientific certainty, infected by 
the same strain of Cronobacter that can be traced back to a contaminated powdered formula made at factory A.
This following is a simulation based on several different investigations.
The purpose is to show by microbial forensic techniques that strains 1, 2, and 3 are a “microbial forensic match” and that strain 4 is a “microbial forensic mis-match” to strains 1–3.
Cronobacter strain 1: isolated from a neonatal meningitis case in a Georgia hospital in June of 2005.
Cronobacter strain 2: isolated from a neonatal meningitis case in a Maryland hospital in March of 2006.
Cronobacter strain 3: isolated during an FDA investigation in April, 2006 from a contaminated piece of production equipment (storage hamper for finished product) at factory A 
“dryer deluge,” “leakey nozzle in dryer.”
Cronobacter strain 4: isolated from a sink drain of the nursery at the Maryland hospital during an investigation of cause of the Maryland case’s meningitis.
Both cases ingested powdered formula made in factory A. They both ingested powdered formula for 1–6 days before they developed meningitis.
November 2015 | Volume 3 | Article 846
Farmer My 40-year history with Cronobacter
Frontiers in Pediatrics | www.frontiersin.org
•	 C. sakazakii ST4 appears to be a stable clone because strains 
have been isolated from 7 countries for > 50 years. The 
earliest non-clinical isolate was isolated in 1950 from a can of 
dried milk.
This illustrates the unique position of C. sakazakii ST4 in 
relation to other Cronobacter species and strains, and in relation 
to meningitis in neonates and babies. This is analogous to the 
unique position of Escherichia coli K1 as a cause of meningitis, 
which is in contrast to other species and strains in the genus 
Escherichia.
The importance of C. sakazakii ST4 is important in a criti-
cal analysis of the statement “Cronobacter is widely distributed 
in the environment.” This should be reframed to the question 
“Cronobacter/E. sakazakii strains have been found in several 
different kinds of environment specimens, but do any of these 
environmental strains have the capability of causing neonatal 
meningitis?”
environmental Stress, injured Cells,  
and the “viable but Non-Culturable”  
State (the “vNC” State)
Facts: Enterobacteriaceae strains including Cronobacter can 
become injured when they are subjected to stress such as heat 
and drying. Bacteria can respond to stress by entering a unique 
physiological state known as the “viable but non-culturable” 
(often abbreviated as the “VNC” state”). Many different studies 
indicate that pathogens in the family Enterobacteriaceae can enter 
this state. These include Escherichia coli O157:H7, Salmonella, 
Shigella, Enterobacter cloacae, Klebsiella, and many others. See the 
review by Oliver (28) for a complete listing and details.
Question: Can Cronobacter strains react to stress conditions 
and pass from a “viable and culturable state” to a “viable but 
non-culturable state?” Until recently Cronobacter had not been 
studied in regard to the viable but non-culturable state. Similarly, 
until recently laboratories had to resort to research procedures 
to look for this phenomenon. However, that there are now com-
mercially available reagents and procedure for reviving, detecting 
and isolating strains of Cronobacter that are in the viable but 
non-culturable state.
Observation 1: At the International Conference on Cronobacter 
(Enterobacter sakazakii), Dublin, Ireland, January 22-23, 2009 the 
first data on the viable but non-culturable state for Cronobacter/E. 
sakazakii was presented. Dr. Angelica Lehner is one of the fore-
most Cronobacter researchers. She works at the Institute of Food 
Safety and Hygiene, University of Zurich, Zurich Switzerland 
and has done experiments using E. sakazakii strain E 601 (ATCC 
29544), which is a non-capsule producer and E. sakazakii strain 
E 602 which produces capsules. She stated that “Cronobacter 
seems to enter a viable but non-culturable state” – see: http://
crono09.tripod.com/lehner.pdf.
Observation 2: The commercial company Sigma Aldrich 
states: “Supplementing the pre-enrichment and enrichment 
broths with ferrioxamine E significantly improved the recovery of 
Salmonella, Cronobacter spp., Staphylococcus aureus and Yersinia 
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enterocolitica from artificially or naturally contaminated foods 
[1–3]. A concentration of ferrioxamine E (available from Sigma, 
see Table 1) in the range of 5–200 ng/mL supports growth (see 
Table 2). … This leads to a reduced lag-phase in the medium and 
reactivates damaged bacteria. The ferrioxamine E is often used 
in Buffered Peptone Water the medium recommended by the 
ISO-Norms for Enterobacteriacea ….” (see Table 3)
Table  4 lists a few ways to “revive” Cronobacter and other 
bacteria from the non-culturable state to the culturable state.
The existence of Cronobacter strains in the “viable but non-
culturable state” is a possible explanation for why a sample of 
powdered infant formula or other product can be tested and 
found “negative for Cronobacter contamination” but is actually 
contaminated with Cronobacter. This explanation would be that 
the lack of a sensitive testing method resulted in a false negative 
test result.
However, further studies are needed to provide a definitive 
answer to the above question. If Cronobacter strains can go from 
a “viable and culturable state” to a “viable but non-culturable 
state” work is needed to establish “frequency of occurrence” in 
different types of environments, particularly in the production of 
powdered infant formula products. It is essential for companies 
that produce these products to evaluate their procedures and final 
product for Cronobacter contaminants that are in the viable but 
non-culturable state. I have seen no evidence that powdered infant 
formula manufacturers have set this up as a general microbiologi-
cal procedure or have done a specific evaluation in its causation 
analysis of a specific case of Cronobacter meningitis. These should 
be done as safety procedure.
The reader is urged to follow the development of this topic 
with frequent literature and internet searches.
isolation, identification, Typing Methods
Facts: Many different methods have been used to isolate and iden-
tify Cronobacter. Some isolation methods are good, but others 
give false negatives for the presence of Cronobacter. Each isola-
tion method has its advantages and disadvantaged, and there is 
an extensive literature describing them. Many different methods 
have been used to identify Cronobacter. Some are good, but others 
give incorrect identifications. Each identification method has its 
advantages and disadvantaged, and there is an extensive literature 
describing them.
Facts: Not all strains identified as Cronobacter are really 
Cronobacter. Similarly, not all strains identified as, or referred 
to, as Enterobacter sakazakii are really Enterobacter sakazakii. 
These incorrect identifications are causing confusion in the 
literature.
Fact. The MPN method is a microbiological culturing method 
and is frequently used to determine the degree of Cronobacter 
contamination in a sample of powdered infant formula and in 
other foods. When the MPN method is used, the resulting report 
states the degree of contamination in terms of MPN per gram of 
the sample, or MPN per 10 g and/or MPN per 100 grams.
Myth: In the MPN method for Cronobacter, one colony form-
ing unit (CFU) represents one viable cell of the Cronobacter 
contaminant. “Total viable counts” are often done by the MPN 
microbiological assay to determine contamination levels. This 
assay assumes that a positive result (positive tube) results from 
one cell of the contaminating bacterium. However, strains of 
Cronobacter can form large masses of adherent cells and can 
also form biofilms. Thus, a positive tube in the MPN assay 
may not have been caused by a single cell. This is illustrated 
in Table 2.
Myth: Two strains of Cronobacter that have the same PFGE 
pattern are the “same strain in a genetic/epidemiological 
sense.”
Myth: Two strains of Cronobacter that have different PFGE 
patterns cannot be the “same strain in a genetic/epidemiological 
sense.”
The reason for the two myths above is that there are too many 
variable in the PFGE laboratory technique to make precise state-
ments such as these.
Strain Preservation
Fact: There are many good methods to preserve strains of 
Cronobacter once they have been isolated and identified.
TABLe 2 | Correlation between the number of Cronobacter sakazakii cells and colony forming units; must probable number values in a 100-g sample of 
a powdered formula product.
Growth form of the C. sakazakii cells in the  
powder formula
Colony forming units  
(cfu) per 100 g
Most probable number 
(mpn) per 100 g
Actual number of cells per 100 g
Single cell 1 1 1
Pair of cells that are joined together 1 1 2
Clump of 100 cells 1 1 100
Clump of 10,000 cellsa 1 1 10,000
Biofilm of 1,000,000 cells 1 1 1,000,000
Biofilm of 1,000,000,000 cells 1 1 1,000,000,000
Colony A in Figure 3b of Farmer et al. (2)b 1 1 1,000,000,000,000
This table is a simulation of how different growth states of a C. sakazakii culture can affect conclusion about the degree of contamination of a powdered infant formula product. In 
the simulation above, one of the three 100 g samples of a powdered infant formula product was tested by the FDA MPN method and found positive for C. sakazakii contamination. 
Depending on the degree of clumping/biofilm formation strikingly different conclusion would be reached on the degree of contamination of the powdered product – contrast the 
results in columns 2 and 3 with column 4.
aA clump of cells such as this would be found at the bottom of the test tube shown in Figure 4, (right side, E. sakazakii strain 38) of Farmer et al. (2).
bAssumptions: the colony weighs 1 g, and a single E. sakazakii cell weighs 1/1,000,000,000,000 of a gram.
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Recommendation: Investigators should permanently preserve 
each Cronobacter strain that isolate and identify in order to allow 
for future study.
Unfortunately, investigators often destroy or discard 
strains of Cronobacter that they have so carefully isolated, 
identified and studied. An employee of the powdered infant 
formula industry stated that in his opinion it is not useful to 
preserve Cronobacter strains isolated from powdered infant 
formula, raw ingredients or from the factory environment. 
Perhaps he was thinking in terms of possible legal liability 
rather than in terms of helping an investigation of the causal 
role of the powdered formula in a case of neonatal meningitis 
following ingestion of powdered formula made in his produc-
tion facility.
Human infections and their epidemiology
Fact: Cronobacter is a cause of neonatal meningitis. This is a 
well-documented fact. Cronobacter is also a well-known cause 
of hospital outbreaks and sporadic cases both in the home and 
hospital.
Myth: Cronobacter causes diarrhea and necrotizing enterocol-
itis (NEC). It is true that Cronobacter has been isolated from cases 
of diarrhea and necrotizing enterocolitis. There is an important 
adage “association does not prove causation,” and this is true for 
these two human illnesses. Additional studies are needed based 
on well-established causation criteria.
Recommendation: Use the wording “Cronobacter has an asso-
ciation with diarrhea and necrotizing enterocolitis rather than 
“Cronobacter causes diarrhea and necrotizing enterocolitis.”
Myth: Cronobacter causes a wide variety of other human 
infections.
Recommendations: I would reword this to: “Cronobacter has 
been isolated from a wide variety of other human infections, but 
in the vast majority of these it was not proven that the organ-
ism was actually causing an infection.” This is the “infection vs. 
colonization” problem. Investigators should use serodiagnostic 
testing to determine if the case had an antibody response to the 
Cronobacter strain that was isolated.
Myth: The incubation period for human neonatal meningitis 
caused by Cronobacter is 3–4  days. It is true that in outbreak 
investigations symptoms developed as soon as 3–4 days after the 
initial ingestion of the implicated formula product. However, 
because of the many variables involved this observation does not 
prove, or even imply, that the incubation period was 3–4 days for 
the cases studied.
Recommendation: I would use this wording: “The incubation 
period for human neonatal meningitis caused by Cronobacter is 
unknown. Because of technical difficulties it will be very hard to 
determine the range and average incubation period.”
Facts: The infectious dose is unknown for human neonatal 
meningitis caused by Cronobacter. The infectious dose and incu-
bation period are also unknown for all other infections caused 
by Cronobacter.
Questions: What does it mean when a Cronobacter strain is 
isolated from a sink drain in the home of an infant who has been 
diagnosed with Cronobacter meningitis and the Cronobacter 
strain found in the sink drain is a “molecular match” to the strain 
isolated from the infant? Does this prove or imply that the home 
environment is the source/cause of the infant’s Cronobacter 
meningitis? No, there are several possible explanations. The 
following is taken from public documents in an actual legal 
case which is based on investigations by government agencies 
including CDC:
There are several possible explanations for the origin of the 
E. sakazakii strain in the left sink drain at the house where the 
infant lived:
TABLe 3 | Recommended end concentration of Ferrioxamine e.
Organisms Nanogram per milliliter
Salmonella 75
Cronobacter spp. (Enterobacter sakazakii) 150
Yersinia enterocolitica 100
See more at: http://www.sigmaaldrich.com/technical-documents/articles/microbiology-
focus/viable-but-nonculturable.html
TABLe 4 | Commercial and non-commercial treatments and reagents 
that have been used to change Cronobacter/E. sakazakii and other 
Enterobacteriaceae from the viable but non-culturable state to the 
culturable state.
Organism Treatment Reference
Cronobacter/Enterobacter 
sakazakii
Commercial Ferrioxamin  
E (FerriOx), 150 ng/mL 
Sigma Aldrich 
Company
Cronobacter/Enterobacter 
sakazakii
In vivo passage in 
re-colonization plant 
model for seeds
Lopez (30)
Campylobacter jejuni Intestinal passage in 
suckling mice (neonatal 
mouse model) 
Oliver (28)
Enterobacteriaceae – various 
species
Numerous ways and 
conditions
Oliver (28)
Escherichia coli Trihydroxamate 
siderophore ferrioxamine
Reissbrodt (31)
Escherichia coli Commercial antioxidant 
Oxyrase
Reissbrodt (31)
Escherichia coli “Enterobacterial 
autoinducer” (a heat-
stable autoinducer 
of growth produced 
by enterobacterial 
species in response to 
norepinephrine)
Reissbrodt (31)
Salmonella serotypes Commercial Ferrioxamin  
E (FerriOx), 75 ng/mL
Sigma Aldrich 
Company
Salmonella Typhimurium Trihydroxamate 
siderophore ferrioxamine
Reissbrodt (31)
Salmonella Typhimurium Commercial antioxidant 
Oxyrase
Reissbrodt (31)
Salmonella Typhimurium “Enterobacterial 
autoinducer” (see above)
Reissbrodt (31)
Yersinia enterocolitica Commercial Ferrioxamin E 
(FerriOx), 100 ng/mL
Sigma Aldrich 
Company
TABLe 5 | Uncertainties associated with assessing the public health risk 
from Cronobacter.
•   Cases of infection that are missed because of inadequate microbiological 
methods for detection, isolation and/or identification
•   Cases that are not reported to local, state and federal health agencies
•   Cases that are identified as Cronobacter infection or colonization but are 
not because of mis-identification of the bacterium that was isolated from 
the clinical specimen
•   Differentiation of infection vs. colonization
•   Incorrect use of the term “Cronobacter infection” – in most instances the 
correct usage is “a clinical microbiology isolate of Cronobacter which was 
not further studied as to infection vs. colonization”
•   Incubation period, infectious dose and strain infectivity in neonatal 
meningitis and other human infections
•   Incorrect assumptions in causation analysis
•   Possible role of throat colonization in neonatal meningitis as a means of 
multiple inoculation of the intestinal tract (as has been shown for Yersinia 
enterocolitica serotype O3)
•   Inaccurate medical records – Example: a twin whose record said he was 
not fed powdered infant formula, but he probably was because of a three 
different identification errors (switches) of his records with those of his twin 
brother who was fed a powdered infant formula)
•   Animal models for infectious dose and incubation period have many 
limitations when extrapolated to human infections
•   Unknown importance environmental reservoirs
•   The original source of the Cronobacter organism isolated in the “blender-
associated cases”
•   The original source of the Cronobacter organism in the “Nursery water 
cases”
•   Importance of strains destroyed, rather than saved, by the powdered infant 
formula industry
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 (1) The strain was present in one of the implicated batches 
of powdered formula made by company A, and it was in 
a “viable and culturable” state. The unused formula was 
poured into the sink. This may have occurred as early as 
October 29 or 30, the date the mother first fed the infant 
formula made from powder. One or more E. sakazakii cells 
in the discarded liquid adhered to the sink drain, probably 
adhering to a biofilm that was already present the drain. The 
E. sakazakii strain from the formula then colonized the sink 
drain, probably as a stable biofilm. The sink drain was later 
tested by CDC and the strain of E. sakazakii was isolated.
 (2) The facts are the same as in number 1 above except E. saka-
zakii in the formula was in a “viable and non-culturable.” 
The favorable environment of the sink allowed E. sakazakii 
to be “revived” and transformed into a “viable and cultur-
able” state. It was later isolated and identified at CDC.
 (3) The facts are the same as in number 1 above except E. saka-
zakii was in the feces of the infant in the days before his E. 
sakazakii infection began, i.e., he had intestinal colonization 
with E. sakazakii. It was then transferred to the sink/sink 
drain by one of many possible mechanisms. One mechanism 
would be the hands of someone who came in contact with 
his feces and then used the sink.
 (4) Something or someone introduced the E. sakazakii into the 
sink. From the sink drain it may have been transferred to 
the infant in some way and then caused his infection. This 
explanation was given by one or more defense experts.
Fact: Not all species/strains of Cronobacter have the same 
pathogenic potential. This was emphasized in the previous dis-
cussion about the importance of Cronobacter sakazakii sequence 
type 4 (C. sakazakii ST 4) in neonatal meningitis.
Animal infections, Animal Models 
of Disease
Fact: There are no known animal infectious diseases caused by 
Cronobacter. Strains of Cronobacter have been isolated for ani-
mals, but these have been in the absence a naturally occurring 
disease process.
Fact: Animal models such as the neonatal rat model have been 
used to study the infectious process and possible virulence factors 
of Cronobacter.
Myth: Results from animal models accurately predict and can be 
extrapolated to the human disease processes to quantify items such 
as infectious dose and incubation period. Although animal models 
have been helpful in the absence of human data they have many 
limitations, and the results should be viewed with caution (29).
environment
Fact or myth?: Cronobacter is widely distributed in the environ-
ment. This is myth or a fact depending on the definition of “widely 
distributed.” A safe way to avoid making this an unanswerable 
question is to stick to the facts and use precise and accurate word-
ing, i.e., write precisely sentences and include references:
Strains of Cronobacter sakazakii have been isolated from the 
following sources: … (References).
Strains of Cronobacter sakazakii sequence type 4 have been 
isolated from the following sources: … (References).
Strains of Cronobacter condomentii have been isolated from the 
following sources: … (References).
Powdered infant Formula industry, and the 
international Formula Council (iFC)
Facts: The powdered infant formula industry and the IFC have 
played an important role in the current status of powdered infant 
formula in the United States in the following areas: manufacture, 
marketing, labeling, warnings, and instructions for preparation 
and use. They have influenced these in many different ways. 
However, it is beyond the scope of this paper to discuss these in 
detail. Several were discussed previously and additional one are 
listed in Tables 5 and 6.
Myth: Manufacturer’s instructions for preparing powdered 
infant formula are complete and definitive in telling preparers 
how to avoid risks of infection by Cronobacter and other patho-
gens. There is there no universal standard or wording that com-
mercial manufacturers of powdered infant formula are required 
to follow in this regard. The powdered infant formula industry 
and FDA have done a very poor job in providing complete 
TABLe 6 | Recommendations based on everything i have learned about Cronobacter over the last 40 years.
To microbiologists
•   Preserve all Cronobacter isolates for future study
•   See previous paragraphs for the many others
To government agencies
•   Make a Cronobacter infection a reportable disease as it’s the case for many other serious infectious diseases. In the United States the state on Minnesota has 
done this, but it is apparently be the only state that has established this reporting requirement
To CDC – additional recommendations to add to your excellent recommendations for safely preparing infant formula
Powder examination steps
•   Examine the powder and other items used in formula preparation carefully before each feeding
•   Examine the powder for insects, insect parts, or other foreign objects. One manufacturer had a serious contamination problem with beetles, beetle larvae, beetle 
parts. They had to recall millions of packages of this adulterated producta (34). In my kitchen simulation experiments I sometimes saw flying and crawling insects in 
the areas around the sink that pose a possible contamination danger to the powdered formula or other items used in formula preparation
water safety steps
•   Always boil the water used in preparing formula, even if it is distilled or bottled water. Bacteria can contaminate water in numerous ways
Safety steps for the scoop used to measure the amount of powdered formula
•   Insert a spoon or long forceps into boiling water for 1 min. This is a disinfection step to kill most germs that may be present
•   Place the disinfected spoon or long forceps of a clean dish that has similarly been disinfected
•   Insert the disinfected spoon or long forceps into the can of powdered infant formula to remove the measuring spoon
•   Place the spoon in a small glass container that similarly been disinfected. Cover with aluminum foil to prevent contamination from germs in the air that can 
contaminate the spoon
•   With your fingers touch only the handle of the scoop and remove it from its container
•   Measure the correct amount of powder. Add water and mix as instructed
•   Place the scoop back into the glass and cover it with foil
•   By doing the above steps you greatly reduce the contamination of the powder with the scoop and your fingers
To CDC – an additional recommendation
•   Do not use the word “infection” in “Cronobacter infection” unless infection has actually been documented
To the powdered infant formula industry
•   Make a product that is free of contamination with Cronobacter, Salmonella, other pathogenic bacteria, other microorganisms, insects, insect parts, or other foreign 
objects
•   Do much more intensive sampling and testing to detect and isolate Cronobacter and other pathogenic bacteria when you are testing for contamination of finished 
powdered formula, raw materials, the factory environment, and items supplied by contractors powdered formula
•   Use sensitive and specific methods in the above testing that isolate and identify both viable and “viable but non-culturable” strains of Cronobacter, Salmonella, and 
other pathogenic bacteria
•   Freeze or otherwise permanently preserved for future study all strains of Cronobacter, Salmonella, and other pathogenic bacteria isolated in the sampling and 
testing described above
•   Notify FDA and when a strain of Cronobacter, Salmonella, or other pathogenic bacteria is isolated in any of the above
•   Permanently preserve samples/cans (“library samples”) of powdered infant formula from each batch/lot made in the production facility. The reason for doing this is 
that additional testing is then possible to rule out or rule in the probable source when a case of infection by Cronobacter, Salmonella, or other pathogenic bacteria 
is reported following ingestion of the powder
•   Implement CDC’s descriptions above (with improvements) for preparing infant formulas safety and add these to the label/instructions for each can of powdered 
infant formula
•   Do not allow water to accumulate on the roof of the production facility! This was a documented problem at a Mead Johnson facility that produced powdered 
formula. The Structure Tech Company stated on its internet site: “Mead Johnson, a division of Bristol-Myers Squibb, was experiencing leakage conditions over 
their manufacturing operations, some of which were sterile environments.” The internet description above was apparently removed after this was damaging 
quotation was revealed in a legal case involving the Mead Johnson facility
To FDA
•   Change from being an advocate of the powdered infant formula industry to being an advocate for public safety
•   Require the powdered infant formula industry to implement the items listed above and those stated in previous paragraphs of this paper
•   Provide documentation why you told the powdered infant formula industry it only needed to test one 333 gram sample of a lot of powdered formula when you own 
data from 2002 showed that this is an inadequate sample size, and that four 333 gram samples were needed to detect Cronobacter contamination
To the international Formula Council
•   Do not distort facts in your role as an advocate for the powdered infant formula industry
•   Do not make ridiculous statements such as “Enterobacter sakazakii is not a pathogen.” You lose all credibility when you act in an irresponsible manner in making a 
statement such as this
To mothers and preparers of powdered infant formula in the home and hospital
•   Do breast feeding whenever possible
•   When you cannot breast feed, use liquid formula rather than powdered infant formula
•   When powdered infant formula is used, carefully read and follow CDC’s detailed description for preparing it more safely
•   Add addtional safety steps listed above to further decrease injection risks
a http://www.fda.gov/Safety/Recalls/ucm226885.htm
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information and instructions. Fortunately, CDC has taken the 
lead and has provided complete and specific instruction for 
preparing powdered infant formula which should greatly reduce 
the risk of Cronobacter infection and infection with other organ-
isms. See: CDC’s information “Cronobacter Illness and Infant 
Formula” found at: http://www.cdc.gov/Features/Cronobacter/ 
and “Cronobacter Illness and Infant Formula” found at: http://
www.cdc.gov/cronobacter/.
Recommendations: Based on published and unpublished 
information and on my personal experiences I have several rec-
ommendations for CDC to improve their excellent instructions/
advice to reduce infection risks during preparation of powdered 
infant formula. These are listed in Table 6.
Searching the Literature
The REFERENCE section below is a recommended starting point 
to learn more about Cronobacter. The key point to remember is 
that beginning in 2007 there was a transition in the usage of 
names from Enterobacter sakazakii to Cronobacter. For this rea-
son, a literature search should use the following terms to capture 
all of the possibilities: “yellow-pigmented Enterobacter cloacae” 
“Enterobacter sakazakii” “E. sakazakii” “Cronobacter sakazakii” 
“C. sakazakii” “sakazakii” and “Cronobacter.” A very simple 
alternative is to use just two terms: “sakazakii” and “Cronobacter,” 
which I have found is very effective. Several papers are highly 
recommended (32, 33, 35–42).
Author Note
This paper expands on many of the topics and ideas in my Keynote 
Lecture “Cronobacter (Enterobacter) sakazakii – Reflections 
on the First 50 Years; Challenges and Unresolved Issues for the 
Next 50,” that I presented at the 1st International Conference on 
Cronobacter (Enterobacter sakazakii), Dublin, Ireland, January 
22, 2009 (43).
References
1. Forsythe SJ. Myths and legends of Cronobacter: a new bacterial pathogen of 
babies?. Microbiol (2012) 1:30–3. 
2. Farmer JJ, III, Asbury MA, Hickman FW, Brenner DJ, and the 
Enterobacteriaceae Study Group. Enterobacter sakazakii: a new species of 
“Enterobacteriaceae” isolated from clinical specimens. Int J Syst Bacteriol 
(1980) 30:569–84. doi:10.1099/00207713-30-3-569
3. Pangalos G. Sur un bacille chromogène isolé par hémoculture. C R Soc Biol 
[Comptes Rendus Seances Soc Biol] (1929) 100:1097–8. 
4. Joseph S, Forsythe SJ. Predominance of Cronobacter sakazakii sequence type 
4 in neonatal infections. Emerg Infect Dis (2011) 17(9):1713–5. doi:10.3201/
eid1709.110260 
5. Joseph S, Desai P, Ji Y, Cummings CA, Shih R, Degoricija L, et al. Comparative 
analysis of genome sequences covering the seven Cronobacter species. PLoS 
One (2012) 7(11):e49455. doi:10.1371/journal.pone.0049455 
6. Urmenyi AMC, White-Franklin AW. Neonatal death from pig-
mented coliform infection. Lancet (1961) 1:313–5. doi:10.1016/
S0140-6736(61)91481-7 
7. Jøker RN, Nørholm T, Siboni KE. A case of neonatal meningitis caused by a 
yellow Enterobacter. Dan Med Bull (1965) 12:128–30. 
8. Brenner DJ. DNA reassociation for the clinical differentiation of enteric 
bacteria. Public Health Lab (1974) 32:118–30. 
9. Steigerwalt AG, Fanning GR, Fife-Asbury MA, Brenner DJ. DNA relatedness 
among species of Enterobacter and Serratia. Can J Microbiol (1976) 22:121–37. 
doi:10.1139/m76-018 
10. Brenner DJ, Farmer JJ III, Hickman FW, Asbury MA, Steigerwalt AG. Taxonomic 
and Nomenclatural Changes in Enterobacteriaceae. HEW Publication No. 
[CDC] 79-8356. Atlanta, GA: Center for Disease Control (1977).
11. Iversen C, Lehner A, Mullane N, Bidlas E, Cleenwerck I, Marugg J, et al. The 
taxonomy of Enterobacter sakazakii: proposal of a new genus Cronobacter gen. 
nov. and descriptions of Cronobacter sakazakii comb. nov. Cronobacter saka-
zakii subsp. sakazakii, comb. nov., Cronobacter sakazakii subsp. malonaticus 
subsp. nov., Cronobacter turicensis sp. nov., Cronobacter muytjensii sp. nov., 
Cronobacter dublinensis sp. nov. and Cronobacter genomospecies 1. BMC Evol 
Biol (2007) 7:64.doi:10.1186/1471-2148-7-64
12. Muytjens HL, Zanen HC, Sonderkamp HJ, Kollee LA, Wachsmuth IK, 
Farmer JJ III. Analysis of eight cases of neonatal meningitis and sepsis due to 
Enterobacter sakazakii. J Clin Microbiol (1983) 18:115–20. 
13. Muytjens HL, Roelofs-Willemse H, Jaspar GH. Quality of powdered substi-
tutes for breast milk with regard to members of the family Enterobacteriaceae. 
J Clin Microbiol (1988) 26:743–6. 
14. Muytjens HL, Kollée LA. Enterobacter sakazakii in neonates: 
causative role of formula? Pediatr Infect Dis J (1990) 9:372–3. 
doi:10.1097/00006454-199005000-00016 
15. Simmons BP, Gelfand MS, Haas M, Metts L, Ferguson J. Enterobacter sakazakii 
infections in neonates associated with intrinsic contamination of a pow-
dered infant formula. Infect Control Hosp Epidemiol (1989) 10(9):398–401. 
doi:10.2307/30144207 
16. FDA. U. S. Food and Drug Administration. Health Professionals Letter on 
Enterobacter sakazakii Infections Associated with Use of Powdered (Dry) Infant 
Formulas in Neonatal Intensive Care Units. Silver Spring, MD: U.S. Food and 
Drug Administration (2002).
17. FDA. U. S. Food and Drug Administration. “Inspection, Collection and to 
Analysis of Powdered Infant Formula for Enterobacter sakazakii (E. saka-
zakii)” – High Priority. (2002). (DOEP #02-18 – FACTS #33044”).
18. Zink D. FDA Field Survey of Powdered Formula Manufacturing, U. S. Food and 
Drug Administration, Food Advisory Committee, Meeting. (2003). Available 
from: http://www.fda.gov/ohrms/dockets/ac/03/slides/3939s1.htm
19. FDA. U. S. Food and Drug Administration. Food Advisory Committee, Meeting 
March 18-19, 2003. (2003). Available from: http://www.fda.gov/ohrms/dock-
ets/ac/03/slides/3939s1.htm
20. World Health Organization (WHO) and Food and Agriculture Organization 
of the United Nations (FAO). Enterobacter sakazakii and Other Microorganisms 
in Powdered Infant Formula. Meeting Report, Microbiology Risk Assessment 
Series, Number 6. Geneva: World Health Organization (2004). 59 p. Available 
from: http://www.fao.org/3/a-y5502e.pdf
21. World Health Organization (WHO) and Food and Agriculture Organization of 
the United Nations (FAO). Enterobacter sakazakii and Salmonella in Powdered 
Infant Formula. Meeting Report, Microbiology Risk Assessment Series, Number 
10. Geneva: World Health Organization (2006). 95 p. Available from: http://
apps.who.int/iris/bitstream/10665/43547/1/9241563311_eng.pdf?ua=1
22. World Health Organization (WHO) and Food and Agriculture Organization 
of the United Nations (FAO). Enterobacter sakazakii (Cronobacter spp.) in 
Powdered Follow-up Formula. Meeting Report, Microbiology Risk Assessment 
Series, Number 15. Geneva: World Health Organization (2008). 86 p. Available 
from: http://www.who.int/foodsafety/publications/micro/MRA_followup.
pdf
23. Farmer JJ III. Enterobacter sakazakii  –  Personal perspectives and reminis-
cences from a 32-year history. Chapter 10. In: Farber JM, Forsythe SJ, editors. 
Enterobacter sakazakii. Washington, DC: ASM Press (2008). p. 255–64.
24. Farber JM, Forsyth SJ, editors. Enterobacter sakazakii. Washington, DC: ASM 
Press (2008). 271 p.
25. Iversen C, Mullane N, McCardell B, Tall BD, Lehner A, Fanning S, et  al. 
Cronobacter gen. nov., a new genus to accommodate the biogroups of 
Enterobacter sakazakii, and proposal of Cronobacter sakazakii gen. nov., 
comb. nov., Cronobacter malonaticus sp. nov., Cronobacter turicensis sp. nov., 
Cronobacter muytjensii sp. nov., Cronobacter dublinensis sp. nov., Cronobacter 
genomospecies 1, and of three subspecies, Cronobacter dublinensis subsp. 
dublinensis subsp. nov., Cronobacter dublinensis subsp. lausannensis subsp. 
November 2015 | Volume 3 | Article 8412
Farmer My 40-year history with Cronobacter
Frontiers in Pediatrics | www.frontiersin.org
nov. and Cronobacter dublinensis subsp. lactaridi subsp. nov. Int J Syst Evol 
Microbiol (2008) 58:1442–47.doi:10.1099/ijs.0.65577-0
26. Brady C, Cleenwerck I, Venter S, Coutinho T, De Vos P. Taxonomic evaluation 
of the genus Enterobacter based on multilocus sequence analysis (MLSA): 
proposal to reclassify E. nimipressuralis and E. amnigenus into Lelliottia 
gen. nov. as Lelliottia nimipressuralis comb. nov. and Lelliottia amnigena 
comb. nov., respectively, E. gergoviae and E. pyrinus into Pluralibacter gen. 
nov. as Pluralibacter gergoviae comb. nov. and Pluralibacter pyrinus comb. 
nov., respectively, E. cowanii, E. radicincitans, E. oryzae and E. arachidis into 
Kosakonia gen. nov. as Kosakonia cowanii comb. nov., Kosakonia radicinci-
tans comb. nov., Kosakonia oryzae comb. nov. and Kosakonia arachidis 
comb. nov., respectively, and E. turicensis, E. helveticus and E. pulveris into 
Cronobacter as Cronobacter zurichensis nom. nov., Cronobacter helveticus 
comb. nov. and Cronobacter pulveris comb. nov., respectively, and emended 
description of the genera Enterobacter and Cronobacter. Syst Appl Microbiol 
(2013) 36:309–19.
27. Farmer JJ III, Boatwright KD, Janda JM. Enterobacteriaceae: Introduction 
and Identification, chapter 42. 9th ed. In: Murray PR, Baron EJ, Jorgensen JH, 
Landry ML, Pfaller MA, editors. Manual of Clinical Microbiology. Washington, 
DC: American Society for Microbiology (2007). p. 649–69.
28. Oliver JD. Recent findings on the viable but non-culturable state 
in pathogenic bacteria. FEMS Microbiol Rev (2009) 34:415–25. 
doi:10.1111/j.1574-6976.2009.00200.x 
29. Farmer JJ III, Potter ME, Riley LW, Barrett TJ, Blake PA, Bopp CA, et  al. 
Animal models to study Escherichia coli O157:H7 isolated from patients with 
haemorrhagic colitis. Lancet (1983) 1:702–703. 
30. Lopez BR, Bashan Y, Bacilio M. Endophytic bacteria of Mammillaria fraileana, 
an endemic rock-colonizing cactus of the southern Sonoran Desert. Arch 
Microbiol (2011) 193:527–41. doi:10.1007/s00203-011-0695-8 
31. Reissbrodt R, Rienaecker I, Romanova JM, Freestone PPE, Haigh RD, Lyte 
M, et  al. Resuscitation of Salmonella enterica serovar Typhimurium and 
enterohemorrhagic Escherichia coli from the viable but nonculturable state 
by heat-stable enterobacterial autoinducer. Appl Environ Microbiol (2002) 
68:4788–94.doi:10.1128/AEM.68.10.4788-4794.2002
32. Besse NG, Leclercq A, Maladen V, Tyburski C, Lombard B. Evaluation 
of the international organization for standardization-international dairy 
federation (ISO-IDF) draft standard method for detection of Enterobacter 
sakazakii in powdered infant food formulas. J AOAC Int (2006) 
89(5):1309–16. 
33. Bowen AB, Braden CR. Invasive Enterobacter sakazakii disease in infants. 
Emerg Infect Dis (2006) 12:1185–9. doi:10.3201/eid1208.051509 
34. FDA. U. S. Food and Drug Administration. FDA Alerts Public Regarding Recall 
of Powdered Infant Formula. Georgia, VT: News Release P02-46 (2002). (29 
different Wyeth products manufactured).
35. Chen Y, Lampel K, Hammack T. Cronobacter. In: Bacteriological Analytical 
Manual. Silver Spring, MD: U.S. Food and Drug Administration (2012). 
Chapter 29. Available from: http://www.fda.gov/Food/FoodScienceResearch/
LaboratoryMethods/ucm289378.htm
36. Gurtler JB, Kornacki JL, Beuchat LR. Enterobacter sakazakii: a coliform of 
increased concern to infant health. Int J Food Microbiol (2005) 104:1–34. 
doi:10.1016/j.ijfoodmicro.2005.02.013 
37. Himelright I, Harris E, Lorch V, Anderson M, Kuehnert M, Forster T, et al. 
Enterobacter sakazakii infections associated with the use of powdered 
infant formula  –  Tennessee, 2001. MMWR Morb Mortal Wkly Rep. (2002) 
51:297–300. 
38. Iversen C, Fanning S. Cronobacter special issue. Int J Food Microbiol (2009) 
136(2):151–246.
39. Jason J. Prevention of invasive Cronobacter infections in young infants fed 
powdered infant formulas. Pediatrics (2012) 130(5):SI1–6. doi:10.1542/
peds.2011-3855 
40. Jones DM, Sutcliffe EM, Curry A. Recovery of viable but non- 
culturable Campylobacter jejuni. J Gen Microbiol (1991) 137:2477–82. 
doi:10.1099/00221287-137-10-2477 
41. Năşcuţiu AM. Viable non-culturable bacteria. Bacteriol Virusol Parazitol 
Epidemiol (2010) 55:11–8 [Article in Romanian]. 
42. Patrick ME, Mahon BE, Greene SA, Rounds J, Cronquist A, Wymore K, et al. 
Incidence of Cronobacter spp. infections, United States, 2003-2009. Emerg 
Infect Dis (2014) 20(9):1520–3. doi:10.3201/eid2009.140545 
43. Farmer JJ III.  Cronobacter (Enterobacter sakazakii) – reflections on the first 
50 years; challenges and unresolved issues for the next 50. 1st International 
Conference on Cronobacter (Enterobacter sakazakii), University College 
Dublin, Ireland, 2009.
Conflict of Interest Statement: The author declares that for over 10  years he 
has done expert witness work in legal cases that involved infants and babies who 
had ingested powdered formula products; became infected with Cronobacter/E. 
sakazakii; and suffered debilitating injury or death. This work included one or more 
of the following: detailed causation analysis, review of documents and procedures 
of the implicated manufacturer of the powdered formula product, written and 
oral reports, and testimony at deposition and trial. He was retained and received 
monetary compensation for this work regardless of the opinions and conclusions 
of his detailed causation analysis. Payments were from plaintiff attorney who 
represented the infant/baby who had suffered debilitating injury or death. The 
defendants in these cases were three U. S. manufacturers of the powdered formula 
product/products that were ingested by the injured infant or baby. Public records 
and non-sealed court documents describe some of the work/testimony described 
above. However, some work/testimony was “sealed by an order of the court,” or was 
covered by a “protective order” that I signed at the beginning of the cases. Thus, 
some of the above has been shielded from public view as a matter of law.
Copyright © 2015 Farmer. This is an open-access article distributed under the terms 
of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
